Abstract
Increased levels of normal B cell precursors, termed hematogones (HGs), are observed in regenerating bone marrow after chemotherapy or hematopoietic stem cell transplantation (HSCT). Recent reports suggest that emergence of HGs is associated with better outcomes following allogeneic HSCT (allo-HSCT). We reviewed the emergence of HGs and the clinical features of 192 patients after allo-BMT. Patients undergoing allo-BMT from related donors were more likely to develop HGs at day 30 compared to unrelated donors. Furthermore, patients undergoing allo-BMT from HLA-mismatched donors were less likely to develop HGs at day 30. The emergence of HGs at day 30 was an independent prognostic factor among patients who underwent BMT. We found no difference in the relapse rate between HG-positive (+) and HG-negative (−) patients undergoing BMT. HG (−) patients had high non-relapse mortality, grade II to IV acute graft-versus-host-disease (GVHD), fungal infection, and lower IgG levels compared to HG (+) patients. The emergence of HGs at day 30 among patients undergoing BMT may be a very useful indicator of subsequent survival outcomes or acute GVHD in common clinical practice.
Similar content being viewed by others
References
Chantepie SP, Cornet E, Salaün V, Reman O (2013) Hematogones: an overview. Leuk Res 11:1404–1411
Chantepie SP, Salaün V, Parienti JJ, Truquet F, Macro M, Cheze S, Vilque JP, Reman O (2011) Hematogones: a new prognostic factor for acute myeloblastic leukemia. Blood 117:1315–1318
Lúcio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen JJ, San Miguel JF (1999) Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 13:419–427
Sevilla DW, Colovai AI, Emmons FN, Bhagat G, Alobeid B (2010) Hematogones: a review and update. Leuk Lymphoma 51:10–19
Babusíková O, Zelezníková T, Kirschnerová G, Kankuri E (2008) Hematogones in acute leukemia during and after therapy. Leuk Lymphoma 49:1935–1944
Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR (2012) Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. Biol Blood Marrow Transplant 18:930–936
Shima T, Miyamoto T, Kikushige Y, Mori Y, Kamezaki K, Takase K, Henzan H, Numata A, Ito Y, Takenaka K, Iwasaki H, Kamimura T, Eto T, Nagafuji K, Teshima T, Kato K, Akashi K (2013) Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation. Blood 121:840–848
Mori J, Ohashi K, Yamaguchi T, Ando M, Hirashima Y, Kobayashi T, Kakihana K, Sakamaki H (2012) Risk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on Acute Kidney Injury Network criteria. Intern Med 51:2105–2110
Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socié G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM (1997) IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 97:855–864
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuk F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U (2013) Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML. Bone Marrow Transplant 48:1257–1259
Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705–712
Gregoire-Gauthier J, Durrieu L, Duval A, Fontaine F, Dieng MM, Bourgey M, de Serre Patey-Mariaud N, Louis I, Haddad E (2012) Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc- mouse model. Bone Marrow Transplant 47:439–50
Cordonnier C, Chevret S, Legrand M, Rafi H, Dhédin N, Lehmann B, Bassompierre F, Gluckman E, GREFIG Study Group (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139:8–18
Feinstein LC, Seidel K, Jocum J, Bowden RA, Anasetti C, Deeg HJ, Flowers ME, Kansu E, Martin PJ, Nash RA, Storek J, Etzioni R, Applebaum FR, Hansen JA, Storb R, Sullivan KM (1999) Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant 5:369–378
Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS (2009) The role of B cells in the pathogenesis of graft-versus-host disease. Blood 114:4919–4927
Acknowledgments
We would like to thank Dr. Makoto Saito for his professional advices in statistical analyses.
Conflict of interest
The authors declare no conflict of interest.
Informed consent
Informed consent was obtained from all patients for being included in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doki, N., Haraguchi, K., Hagino, T. et al. Clinical impact of hematogones on outcomes of allogeneic hematopoietic stem cell transplantation. Ann Hematol 94, 2055–2060 (2015). https://doi.org/10.1007/s00277-015-2492-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-015-2492-y